Johnson & Johnson Supports Efforts to Combat MDR-TB

Johnson & Johnson (J&J) and its partners are working to increase access to treatment for MDR-TB patients around the world.

Since first approval in December 2012, we have provided more than 52,000 courses of SIRTURO® (bedaquiline) to patients in 95 countries, including 29 of the 30 countries with the highest burden of MDR-TB. Beyond this, we have worked with high-burden countries to strengthen health infrastructure to detect and combat MDR-TB and raise community awareness about TB. We are also driving innovation – including in partnership with India’s Institute of Microbial Technology (IMTECH) – to identify next-generation therapies.

Below are a few recent highlights from our work:

CHINA

On February 24, the first dose of bedaquiline was delivered to an MDR-TB patient at Beijing Chest Hospital in China – a major milestone in one of the countries hardest hit by MDR-TB. On March 25, on the heels of World TB Day, J&J and the Chinese government hosted an official medical launch of bedaquiline through China’s New Drug Introduction and Protection Program (NDIP) in Beijing. The program will initially provide free access to bedaquiline for approximately 1,000 MDR-TB patients across 15 hospitals in China, through J&J’s Bedaquiline Donation Program with USAID.

RUSSIA/GLOBAL

In March, Janssen signed a Memorandum of Understanding with Russia’s Pharmstandard that will enable Pharmstandard to manufacture bedaquiline for global export. This builds on a long-standing partnership between the two companies; in 2012, Janssen granted commercial rights, as well as certain technology and production know-how, for bedaquiline to Pharmstandard for use in the Russian Federation and a number of other countries in the regions, including the Commonwealth of Independent States (CIS). This new agreement will ultimately provide additional manufacturing capacity for bedaquiline, which will be critical as global access expands.
NEW REGISTRATIONS: JAPAN, UGANDA AND CAMEROON

In the first quarter of 2018, bedaquiline received registration in three additional countries: Japan, Uganda and Cameroon. Since its first approval by the U.S. FDA in 2012, bedaquiline has been registered in 54 countries worldwide, representing over 80 percent of the global burden of MDR-TB. It is also available through the Stop TB Global Drug Facility to more than 100 Global Fund-eligible countries.

UKRAINE

Given the high burden of MDR-TB in Ukraine, identifying a way to register bedaquiline in the country was one of J&J’s highest programmatic priorities over the past several months. Janssen previously granted Pharmstandard the rights to manufacture, register, distribute and sell bedaquiline in Ukraine. Unfortunately, recent political events in Ukraine have interfered with the registration process for bedaquiline.

To expedite the registration and availability of bedaquiline for MDR-TB patients in Ukraine, Janssen and Pharmstandard recently agreed that Janssen, part of the J&J family of companies, will submit a Marketing Authorization Application in its own name in Ukraine. Janssen’s Kiev office has submitted the application for registration and is in the process preparing a registration dossier for submission to the State Expert Center of the Ministry of Health of Ukraine.

SOUTH AFRICA

Around World TB Day, J&J partnered with the South African Broadcasting Corporation (SABC) and USAID to produce a four-part documentary series called Thiba: The Fight Against TB. The aim of the series was to raise awareness of the disease and reduce stigma in order to prevent transmission, encourage patients to seek treatment, and improve patient outcomes.

J&J also partnered with the South African Department of Health, USAID and Mango Airlines to run TB awareness campaigns at O.R. Tambo International Airport in Johannesburg and King Shaka International Airport in Durban. The campaigns provided information about the best ways to prevent transmission of TB through interactive booths, stickers, posters/banners and radio and television announcements.

PHILIPPINES

Johnson & Johnson partnered with CNN in the Philippines on a “Story of the Filipino” feature focused on TB. The segment tells the story of a woman diagnosed with MDR-TB, with the aim of raising awareness about TB and reducing stigma.